Question to the Department of Health and Social Care:

To ask Her Majesty's Government what assessment they have made of international attempts to reform antibiotic reimbursement and of the potential for domestic level reform in that policy field.

The United Kingdom supports the introduction of better incentives to bring new antimicrobials – in particular antibiotics - to market, including through reforms to pharmaceutical reimbursement models. Internationally, we are working with G20 partners to decide how best to deliver the 2017 G20 Leaders’ commitment to “examine practical market incentive options” this year. To inform our approach, the UK tracks the position of other countries and the European Union regarding market incentives, as well as recent research findings such as DRIVE-AB (Driving reinvestment in research and development for antibiotics and advocating their responsible use), looking at the societal value of new antibiotics. Nationally, the Government is working with industry and experts to develop a health technology assessment led evaluation and reimbursement model that supports good antimicrobial stewardship.